+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis

Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis

Digestive Diseases and Sciences 26(8): 718-722

The antipyrine metabolic clearance rate (MCR) was studied in two groups of patients with similar degrees of cholestasis and hepatic damage, but differing mechanisms of cholestasis. The plasma disappearance rate of antipyrine in 18 patients with extrahepatic cholestasis and 11 patients with intrahepatic cholestasis was compared with that of two groups of control subjects without liver disease who were matched for age. Whereas no significant difference was observed for the antipyrine MCR between patients with extrahepatic cholestasis and their controls [30.7 +/- 11.2 (SD) as against 31.6 +/- 10.0 ml/min], the antipyrine MCR was significantly lower (P less than 0.001) in the patients with intrahepatic cholestasis than in their controls (16.2 +/- 4.5 vs 37.4 +/- 17.3 ml/min). These results suggest that cholestasis per se does not change the rate of metabolism of drugs by the liver. The decrease of antipyrine MCR in patients with intrahepatic cholestasis could be due to a reduced functional parenchymal mass related to some degree of hepatic necrosis.

(PDF emailed within 1 workday: $29.90)

Accession: 042530184

Download citation: RISBibTeXText

PMID: 7261836

Related references

Metabolic clearance rate of antipyrine and hepatic microsomal drug oxidizing enzymes in extrahepatic cholestasis. Liver 1(2): 128-129, 1981

NR1H4 analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations. Clinics and Research in Hepatology and Gastroenterology 36(6): 569-573, 2013

Hepatic cholestasis factor (lymphokines) in drug-induced allergic intrahepatic cholestasis. Nihon Shokakibyo Gakkai Zasshi 74(5): 548-556, 1977

Symposion B: Experimental cholestasis--in vitro metabolism and in vivo metabolic clearance of hexobarbital in rats with ANIT-cholestasis. Verhandlungen der Deutschen Gesellschaft für Innere Medizin 82 Pt 1: 269-271, 1976

Extrahepatic cholestasis. I. Histologic changes in hepatic interlobular bile ducts and ductules in extrahepatic cholestasis. American Journal of Clinical Pathology 32(1): 1-4, 1959

Quantitative determination of lipoprotein-X (LP-X) in extrahepatic cholestasis and intrahepatic cholestasis. Revista Medica de Chile 112(3): 233-237, 1984

Experimental cholestasis metabolism in vitro and metabolic clearance in vivo of hexo barbital in rats with alpha naphthyl iso thio cyanate cholestasis. Verhandlungen der Deutschen Gesellschaft fuer Innere Medizin 82(PART 1): 269-271, 1976

Possibilities and limits of ultrasonic tomography in extrahepatic cholestasis. I: Differential diagnosis of extra from intrahepatic-induced cholestasis. Zeitschrift für Arztliche Fortbildung 79(13): 559-561, 1985

Effects of extrahepatic cholestasis ehc on four rate limiting enzymes of hepatic cholesterol xol metabolism. Gastroenterology 102(4 PART 2): A828, 1992

Studies on drug-induced allergic intrahepatic cholestasis--hepatic cholestasis induced in dogs by lymphocyte culture supernatant. Gastroenterologia Japonica 14(1): 19-23, 1979

Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: Low GGT cholestasis is a clinical continuum. Journal of Hepatology 36(3): 439-443, 2002

Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Practice and Research. Clinical Gastroenterology 24(5): 541-553, 2011

Extrahepatic cholestasis in the dog and the differentiation of extrahepatic and intrahepatic cholestasis. Veterinary Quarterly 8(2): 150-157, 1986

The metabolic clearance rate of antipyrine: a good index for the assessment of the hepatic drug-oxidizing function in cirrhotic patients. La Nouvelle Presse Medicale 7(46): 4209-4211, 1978

Extrahepatic ischemia-reperfusion injury reduces hepatic oxidative drug metabolism as determined by serial antipyrine clearance. Pharmaceutical Research (new York). 14(1): 67-72, 1997